In this episode, I’ll discuss labetalol-induced hyperkalemia in acute aortic dissection.
When you think of drug-induced hyperkalemia, what probably comes to mind is some combination of renin–angiotensin–aldosterone system (RAAS) inhibitors, renal dysfunction, or potassium-sparing diuretics. However, non-selective beta-blockers such as labetalol may also cause hyperkalemia. This happens because when beta-2 receptors are blocked, potassium cannot be pumped into cells, leaving it stranded in extracellular spaces like plasma. In many patients, this goes unnoticed, especially if renal function is sufficient to remove excess potassium but in some patients the effect may be clinically significant. A group of authors published such a case in the AJHP.
The case is that of a 59-year-old male with a history of hypertension, diabetes, asthma, and polysubstance use disorder who presented with severe chest pain and hypertensive emergency with a blood pressure that exceeded 240/130 mmHg. The patient had confirmed acute type B aortic dissection upon imaging. Initial management was with IV esmolol and nicardipine, and this was transitioned to oral labetalol up to 600 mg. The authors describe how the patient developed persistent, non-hemolyzed hyperkalemia in the range of 5.2 to 5.8 mmol/L which temporally correlated with labetalol dose escalation. This occured despite preserved renal function and the absence of other medications that might cause hyperkalemia.
After surgical repair of the aorta, labetalol was stopped and replaced with the cardioselective beta-blocker, carvedilol. Within 48 hours the patient’s serum potassium was within normal limits and remained so without further intervention. The Naranjo Adverse Drug Reaction Probability Scale assessment score was 7, indicating a probable adverse drug reaction.
The authors concluded:
Labetalol may induce clinically significant hyperkalemia independent of renal impairment or typical precipitating medications. This case highlights the importance of monitoring K+ in patients receiving labetalol for acute aortic syndromes and supports carvedilol as a potentially safer non-selective beta-blocker alternative with respect to K+ homeostasis.
Pharmacists should keep in mind this potential consequence of using high-dose labetalol and monitor potassium levels accordingly.
To get access to my free download area with 20 different resources to help hospital pharmacists go to pharmacyjoe.com/free.
If you like this post, check out my book – A Pharmacist’s Guide to Inpatient Medical Emergencies: How to respond to code blue, rapid response calls, and other medical emergencies.
Leave a Reply